Single-center, Open-label Study: Immunogenicity and Safety Observation After Vaccination With ACYW135 Meningococcal Polysaccharide Vaccine in Junior High School Students Aged 13-15 Years

• Healthy individuals who meet the observation age range for this immunogenicity/safety study (13-15 years old) and are determined by the researchers based on their medical history.
• Obtain informed consent from the participant's guardian and have them sign the informed consent form.
• The participants and their guardians can adhere to the requirements of the clinical research protocol and persist in participating in the entire follow-up process.
• You have not received any other vaccines (including commercially available vaccines or investigational vaccines) within 30 days prior to the vaccination of the study vaccine.
• Before the age of 7, complete 4 doses of meningococcal vaccine according to the immunization program requirements (non-EPI vaccines are allowed to be used to replace corresponding doses).

Exclusion Criteria:

• Individuals who are known to be allergic to any component of this vaccine;
• Individuals who, upon evaluation by the researchers, are deemed unsuitable for participation in this study;
• Individuals with a history of vaccine or drug allergies (including but not limited to anaphylactic shock, allergic laryngeal edema, allergic purpura, and local allergic necrosis reaction (Arthus reaction)).
• Individuals with a history of epilepsy, convulsions, brain disorders, and allergies.
• People with kidney disease, heart disease, and active tuberculosis.
• Screen for individuals who have experienced fever, acute illnesses, or are in the acute phase of chronic diseases within the past three days.